Safety and effectiveness of replacement with biosimilar growth hormone in adults with growth hormone deficiency: results from an international, post-marketing surveillance study (PATRO Adults)

Ítems similars

• Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope(®)): data from the PATRO Adults study
  per: Beck-Peccoz, Paolo, et al.
  Publicat: (2020)
• SAT-437 The Patro Adults Study of Omnitrope® for the Treatment of Adult Patients with Growth Hormone Deficiency: Latest Safety Outcomes Including Diabetes Risk
  per: Beck-Peccoz, Paolo, et al.
  Publicat: (2019)
• No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study
  per: Beck-Peccoz, Paolo, et al.
  Publicat: (2019)
• Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies
  per: Lundberg, Elena, et al.
  Publicat: (2020)
• Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope(®) for the treatment of adult patients with growth hormone deficiency
  per: Beck-Peccoz, Paolo, et al.
  Publicat: (2012)